<DOC>
	<DOCNO>NCT02914977</DOCNO>
	<brief_summary>In pilot study , eligible patient treat 5 day low dose daunorubicin one cycle . Any patient receives treatment protocol evaluable toxicity . Each patient assess development toxicity schedule visit ( Days 1-5 ) . Following participation brief pharmacodynamic trial , patient proceed conventional investigational therapy , clinically indicate .</brief_summary>
	<brief_title>Low-Dose Daunorubicin Relapsed/Refractory Acute Leukemia</brief_title>
	<detailed_description>Disease relapse remain primary challenge treatment acute myeloid leukemia ( AML ) acute lymphocytic leukemia ( ALL ) . There standard care treatment option relapse acute leukemia , investigational therapy recommend . Clinically target leukemia stem cell ( LSC ) remain unmet need AML ALL . Therefore , primary objective trial determine molecular pharmacodynamic effect low dose daunorubicin ( DNR ) beta-catenin phosphorylation serial bone marrow sample patient relapse leukemia . Prior study low-dose DNR complex , multi-agent regimen , essential confirm inhibit p-beta-catenin S552 human . This pilot study design assess feasibility tolerability low dose DNR administration patient relapsed/refractory AML ALL , obtain preliminary data regard target engagement . A second objective demonstrate safety feasibility low-dose daunorubicin administration patient relapsed/refractory acute leukemia . Beta-catenin phosphorylation measure immunohistochemistry assay bone marrow sample take patient study entry Day 8 follow study therapy low-dose DNR . The investigator also measure pharmacokinetics low dose DNR patient , enable preliminary PK-PD analysis essentially PK data DNR comparable dos use modern analytical methodology . Following participation brief pharmacodynamic proof-of-concept trial , patient proceed conventional investigational therapy , clinically indicate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Ability understand willingness sign write informed consent parental consent . Age ≥ 18 year Pathological confirmation bone marrow document follow : 1 . AML relapse Complete Remission 2 . AML refractory two prior induction attempt 3 . ALL relapse Complete Remission 4 . ALL refractory two prior induction attempt Disease status allow delay additional antileukemia therapy duration study ( hydroxyurea allow control WBC throughout study ) Eastern Cooperative Oncology Group ( ECOG ) performance status score 03 Able adhere study visit schedule protocol requirement Cardiac ejection fraction ≥45 % ECHO Serum alanine aminotransferase aspartate aminotransferase &lt; 3 time ULN Women childbearing potential men partner childbearing potential must agree use adequate contraception prior study entry , duration study participation , 90 day follow completion therapy . Concurrent use conventional investigational anticancer agent , except hydroxyurea ( Standard prophylactic antiinfectives medication prevent/treat tumor lysis syndrome allow . Hydroxyurea may use keep WBC &lt; 25,000 . Additional antileukemia therapy prohibit study. ) . Patient receive chemotherapy radiotherapy within 2 week prior enter study recover adverse event due agent administer 2 week earlier , exception hydroxyurea . Patients know active uncontrolled central nervous system ( CNS ) leukemia History allergic reaction attribute compound similar chemical biologic composition daunorubicin Patients total lifetime anthracycline exposure exceed equivalent 900 mg/m2 daunorubicin Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Unwilling unable undergo serial bone marrow aspirate/biopsy Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>